Trial Outcomes & Findings for Mild Cognitive Impairment and Obstructive Sleep Apnea (NCT NCT01482351)

NCT ID: NCT01482351

Last Updated: 2019-03-06

Results Overview

Memory (immediate and delayed recall) will be assessed using HVLT-R. HVLT-R has been used in elders with Alzheimer's Disease and takes 10 minutes to complete. Total score ranges from 0 to 60, a higher score indicates a better memory (better outcome).

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

54 participants

Primary outcome timeframe

Change from baseline at 6 months and 1 year

Results posted on

2019-03-06

Participant Flow

From 9/2012 to 12/2014, study investigators identified potential participants from clinical practices, advertisements in newspapers, clinical trials registries, senior centers, advertisements in public transportation centers, the Alzheimer's Association, and support groups.

Participant milestones

Participant milestones
Measure
Experimental: MCI/OSA/CPAP Adherent and Non-adherent
All participants were diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score greater than or equal to 10. CPAP was prescribed for nightly use. At baseline there were 68 participants had OSA (AHI ≥10). 14 persons withdrew prior to 6 month testing. There were 54 active MCI participants with OSA at 6 months and 12 month: 29 were CPAP adherent and 25 were CPAP non-adherent.
Overall Study
STARTED
68
Overall Study
6 Months
54
Overall Study
12 Months
54
Overall Study
COMPLETED
54
Overall Study
NOT COMPLETED
14

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Only 45 of the 54 participants provided income data.

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Total
n=54 Participants
Total of all reporting groups
Age, Continuous
67.4 years
STANDARD_DEVIATION 7.2 • n=29 Participants
73.2 years
STANDARD_DEVIATION 8.6 • n=25 Participants
70.1 years
STANDARD_DEVIATION 8.3 • n=54 Participants
Sex: Female, Male
Female
9 Participants
n=29 Participants
15 Participants
n=25 Participants
24 Participants
n=54 Participants
Sex: Female, Male
Male
20 Participants
n=29 Participants
10 Participants
n=25 Participants
30 Participants
n=54 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=29 Participants
0 Participants
n=25 Participants
0 Participants
n=54 Participants
Race (NIH/OMB)
Asian
1 Participants
n=29 Participants
1 Participants
n=25 Participants
2 Participants
n=54 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=29 Participants
0 Participants
n=25 Participants
0 Participants
n=54 Participants
Race (NIH/OMB)
Black or African American
4 Participants
n=29 Participants
13 Participants
n=25 Participants
17 Participants
n=54 Participants
Race (NIH/OMB)
White
24 Participants
n=29 Participants
11 Participants
n=25 Participants
35 Participants
n=54 Participants
Race (NIH/OMB)
More than one race
0 Participants
n=29 Participants
0 Participants
n=25 Participants
0 Participants
n=54 Participants
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=29 Participants
0 Participants
n=25 Participants
0 Participants
n=54 Participants
Region of Enrollment
United States
29 participants
n=29 Participants
25 participants
n=25 Participants
54 participants
n=54 Participants
Education
26 participants
n=29 Participants
21 participants
n=25 Participants
47 participants
n=54 Participants
Married/Cohabitate
23 participants
n=29 Participants
8 participants
n=25 Participants
31 participants
n=54 Participants
BMI
30.3 kg/m^2
STANDARD_DEVIATION 6.7 • n=29 Participants
29.5 kg/m^2
STANDARD_DEVIATION 6.5 • n=25 Participants
29.9 kg/m^2
STANDARD_DEVIATION 6.6 • n=54 Participants
Income - <$20,000
3 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
9 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
12 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
Income - $20,000 - $39,999
2 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
2 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
4 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
Income - $40,000 - $69,999
3 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
4 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
7 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
Income - $70,000 - $99,999
4 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
2 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
6 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
Income - >$100,000
12 Participants
n=24 Participants • Only 45 of the 54 participants provided income data.
4 Participants
n=21 Participants • Only 45 of the 54 participants provided income data.
16 Participants
n=45 Participants • Only 45 of the 54 participants provided income data.
Study Partner-Spouse/cohabitate
26 Participants
n=29 Participants
9 Participants
n=25 Participants
35 Participants
n=54 Participants
Study Partner-Adult child
1 Participants
n=29 Participants
6 Participants
n=25 Participants
7 Participants
n=54 Participants
Study Partner-Other
2 Participants
n=29 Participants
10 Participants
n=25 Participants
12 Participants
n=54 Participants
Reported/known conditions-Diabetes
7 Participants
n=29 Participants
8 Participants
n=25 Participants
15 Participants
n=54 Participants
Reported/known conditions-Cardiovascular Disease
11 Participants
n=29 Participants
14 Participants
n=25 Participants
25 Participants
n=54 Participants
Reported/known conditions-Hypertension
15 Participants
n=29 Participants
14 Participants
n=25 Participants
29 Participants
n=54 Participants
Apolipoprotein E (ApoE)-E2/E2
0 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
1 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
ApoE-E2/E3
1 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
0 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
ApoE-E2/E4
1 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
0 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
1 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
ApoE-E3/E3
16 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
18 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
34 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
ApoE-E3/E4
9 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
4 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
13 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
ApoE-E4/E4
0 Participants
n=27 Participants • Only 52 of the 54 participants provided data.
2 Participants
n=25 Participants • Only 52 of the 54 participants provided data.
2 Participants
n=52 Participants • Only 52 of the 54 participants provided data.
Medications-Cholinesterase inhibitors
1 Participants
n=29 Participants
2 Participants
n=25 Participants
3 Participants
n=54 Participants
Medications-NMDA Receptor Antagonist
0 Participants
n=29 Participants
0 Participants
n=25 Participants
0 Participants
n=54 Participants
Medications-Opioid Analgesics
0 Participants
n=29 Participants
3 Participants
n=25 Participants
3 Participants
n=54 Participants
Medications-Antidepressants
6 Participants
n=29 Participants
1 Participants
n=25 Participants
7 Participants
n=54 Participants
Medications-Sedatives/anxiolytics
5 Participants
n=29 Participants
5 Participants
n=25 Participants
10 Participants
n=54 Participants
Medications-Antihypertensives
19 Participants
n=29 Participants
21 Participants
n=25 Participants
40 Participants
n=54 Participants
Medications-Cholesterol medications
21 Participants
n=29 Participants
18 Participants
n=25 Participants
39 Participants
n=54 Participants
MMSE
28.3 units on a scale
STANDARD_DEVIATION 1.4 • n=29 Participants
28.0 units on a scale
STANDARD_DEVIATION 2.1 • n=25 Participants
28.2 units on a scale
STANDARD_DEVIATION 1.7 • n=54 Participants
CDR
0.5 units on a scale
STANDARD_DEVIATION 0.3 • n=29 Participants
0.7 units on a scale
STANDARD_DEVIATION 0.7 • n=25 Participants
0.6 units on a scale
STANDARD_DEVIATION 0.5 • n=54 Participants
ESS
8.5 units on a scale
STANDARD_DEVIATION 3.5 • n=29 Participants
9.3 units on a scale
STANDARD_DEVIATION 5.3 • n=25 Participants
8.9 units on a scale
STANDARD_DEVIATION 4.4 • n=54 Participants
BDI-II
7.7 units on a scale
STANDARD_DEVIATION 4.6 • n=29 Participants
6.4 units on a scale
STANDARD_DEVIATION 6.6 • n=25 Participants
7.1 units on a scale
STANDARD_DEVIATION 5.6 • n=54 Participants
ARES - Total sleep time
441.0 minutes
STANDARD_DEVIATION 107.0 • n=29 Participants
334.2 minutes
STANDARD_DEVIATION 35.6 • n=25 Participants
374.3 minutes
STANDARD_DEVIATION 84.0 • n=54 Participants
ARES - Apnea-Hypopnea Index
21.3 events/hour
STANDARD_DEVIATION 7.8 • n=29 Participants
14.6 events/hour
STANDARD_DEVIATION 2.7 • n=25 Participants
17.1 events/hour
STANDARD_DEVIATION 5.8 • n=54 Participants
ARES - Lowest oxygen saturation
83.6 percentage of blood oxygen saturation
STANDARD_DEVIATION 4.3 • n=29 Participants
82.9 percentage of blood oxygen saturation
STANDARD_DEVIATION 2.8 • n=25 Participants
83.1 percentage of blood oxygen saturation
STANDARD_DEVIATION 3.1 • n=54 Participants
PSG - Total sleep time
283.2 minutes
STANDARD_DEVIATION 84.0 • n=29 Participants
270.5 minutes
STANDARD_DEVIATION 95.9 • n=25 Participants
279.0 minutes
STANDARD_DEVIATION 86.7 • n=54 Participants
PSG - Apnea-Hypopnea Index
25.3 events/hour
STANDARD_DEVIATION 11.5 • n=29 Participants
31.1 events/hour
STANDARD_DEVIATION 20.8 • n=25 Participants
27.2 events/hour
STANDARD_DEVIATION 15.0 • n=54 Participants
PSG - Lowest oxygen saturation
82.3 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.9 • n=29 Participants
81.8 percentage of blood oxygen saturation
STANDARD_DEVIATION 5.0 • n=25 Participants
82.2 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.3 • n=54 Participants
Split-night PSG - Total sleep time
218.2 minutes
STANDARD_DEVIATION 150.6 • n=29 Participants
150.4 minutes
STANDARD_DEVIATION 77.4 • n=25 Participants
166.1 minutes
STANDARD_DEVIATION 95.7 • n=54 Participants
Split-night PSG - Apnea-Hypopnea index
25.6 events/hour
STANDARD_DEVIATION 9.2 • n=29 Participants
14.6 events/hour
STANDARD_DEVIATION 7.8 • n=25 Participants
17.7 events/hour
STANDARD_DEVIATION 9.4 • n=54 Participants
Split-night PSG - Lowest oxygen saturation
86.0 percentage of blood oxygen saturation
STANDARD_DEVIATION 5.0 • n=29 Participants
82.9 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.3 • n=25 Participants
83.8 percentage of blood oxygen saturation
STANDARD_DEVIATION 6.0 • n=54 Participants

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants lost to follow-up prior to 6-months testing.

Memory (immediate and delayed recall) will be assessed using HVLT-R. HVLT-R has been used in elders with Alzheimer's Disease and takes 10 minutes to complete. Total score ranges from 0 to 60, a higher score indicates a better memory (better outcome).

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Hopkins Verbal Learning Test-Revised (HVLT-R)
Baseline
23.52 score on a scale
Standard Deviation 5.56
20.04 score on a scale
Standard Deviation 5.30
Hopkins Verbal Learning Test-Revised (HVLT-R)
6-month
23.68 score on a scale
Standard Deviation 5.08
20.39 score on a scale
Standard Deviation 5.48
Hopkins Verbal Learning Test-Revised (HVLT-R)
1 year
23.59 score on a scale
Standard Deviation 5.73
20.82 score on a scale
Standard Deviation 5.69

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants lost to follow-up prior to 6-months testing.

The Digit Symbol subtest (DS) from the Wechsler Adult Intelligence Scale (WAIS-R) was used to measure psychomotor/cognitive processing speed. An age-adjusted total scaled score was used for analysis. The adjusted total score ranges from -5.7 to+27. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Digit Symbol Subtest (DS)
Baseline
9.18 score on a scale
Standard Deviation 2.59
8.06 score on a scale
Standard Deviation 2.65
Digit Symbol Subtest (DS)
6-months
9.90 score on a scale
Standard Deviation 2.74
8.02 score on a scale
Standard Deviation 2.36
Digit Symbol Subtest (DS)
1 year
10.21 score on a scale
Standard Deviation 3.03
8.09 score on a scale
Standard Deviation 2.78

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants lost to follow-up prior to 6-months testing.

Global cognitive function will be assessed using MMSE. It is a 30-item cognitive screen measuring orientation, registration, short-term memory, attention/concentration, language, and constructional capacity. Summary score will be used as a measure of global cognitive function. Total score ranges from 0 to 30, equal to and above 24 is normal (better outcome), less than 21 indicates increasing odds of dementia (worse outcome).

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Mini Mental State Evaluation Exam (MMSE)
Baseline
28.34 score on a scale
Standard Deviation 1.40
28.00 score on a scale
Standard Deviation 2.10
Mini Mental State Evaluation Exam (MMSE)
6-month
28.61 score on a scale
Standard Deviation 1.62
27.48 score on a scale
Standard Deviation 2.00
Mini Mental State Evaluation Exam (MMSE)
1-year
27.93 score on a scale
Standard Deviation 2.05
26.43 score on a scale
Standard Deviation 2.46

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants were lost to follow-up prior to 6-months testing.

Attention will be measured using SCW. We used the Golden and Freshwater's (2002) version. This version provides paper stimuli for each trial: in the first, columns of the words"red""blue" and "green" are printed in black ink (Word Reading; W); in the second, columns of the same words are printed in red, blue, or green ink (Color Naming; C); in the third, the words "red" "blue" and "green" are printed in a colored ink (red, blue or green) that does not match the word (Color-Word; CW). Participants read each page aloud as quickly as possible for 45 seconds and receive a score for each trial representing the number of items correctly read aloud. The Interference T-score is obtained by first calculating a deviation score by subtracting a predicted CW score from the obtained raw CW score (in 45s). The obtained deviation score is then converted to an Interference T-score. Lower T scores(T\<40) in the Interference condition show reductions in inhibitory control.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Stroop Color and Word Test (SCW)
6-month
48.22 score on a scale
Standard Deviation 8.20
45.36 score on a scale
Standard Deviation 8.57
Stroop Color and Word Test (SCW)
Baseline
47.36 score on a scale
Standard Deviation 6.15
44.28 score on a scale
Standard Deviation 8.19
Stroop Color and Word Test (SCW)
1-year
50.00 score on a scale
Standard Deviation 7.40
45.14 score on a scale
Standard Deviation 9.47

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants were lost to follow-up prior to 6-months testing.

Attention/reaction time will assessed using the PVT. The participants sat in a closed and quiet examination room, without any auditory or visual disturbance. A 1-minute mock PVT demonstration was done prior to each test. The PVT visual display was held 14-22 inches from the subject's eyes. The participants were asked to either use the index finger or thumb of their dominant hand to respond to the PVT signals. The participants were instructed to maintain the fastest possible reaction times to a simple visual stimulus: a red light emitting diode displaying time in milliseconds in a window of the portable PVT device. We used number of lapses, defined as mean reaction time above 500 milliseconds (errors of omission) as the primary outcome. Lower score indicates better outcomes (Less lapses).

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
The Psychomotor Vigilance Task (PVT)
6-month
2.58 score on a scale
Standard Deviation 1.64
4.29 score on a scale
Standard Deviation 2.71
The Psychomotor Vigilance Task (PVT)
Baseline
3.09 score on a scale
Standard Deviation 1.53
6.46 score on a scale
Standard Deviation 3.66
The Psychomotor Vigilance Task (PVT)
1-year
2.77 score on a scale
Standard Deviation 1.91
4.76 score on a scale
Standard Deviation 2.94

PRIMARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants were lost to follow-up prior to 6-months testing.

Daytime sleepiness be assessed using ESS. The ESS asks the respondent to rate the likelihood of falling asleep in eight specific situations using a four-point Likert scale ranging from never dozing to high chance of dozing. The scale significantly correlates with the frequency of apneas and is a clinical and research standard for the assessment of daytime sleepiness. The total score ranges from 0 to 24, a higher score indicates higher chance of daytime sleepiness (worse outcome).

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Epworth Sleepiness Scale [ESS]
1-year
6.34 score on a scale
Standard Deviation 3.71
7.57 score on a scale
Standard Deviation 4.37
Epworth Sleepiness Scale [ESS]
Baseline
8.50 score on a scale
Standard Deviation 3.52
9.32 score on a scale
Standard Deviation 5.34
Epworth Sleepiness Scale [ESS]
6-months
6.54 score on a scale
Standard Deviation 3.17
8.00 score on a scale
Standard Deviation 5.53

SECONDARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants were lost to follow-up prior to 6-months testing.

Everyday function will be assessed using FOSQ. It is a 30-item Likert-scale, self-report, disease-specific functional status measure written at the 4th grade level. The total score ranges from 0 to 120, a higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Functional Outcomes Sleep Questionnaire (FOSQ)
Baseline
17.31 score on a scale
Standard Deviation 1.99
17.34 score on a scale
Standard Deviation 2.66
Functional Outcomes Sleep Questionnaire (FOSQ)
6-month
18.17 score on a scale
Standard Deviation 1.48
18.13 score on a scale
Standard Deviation 2.14
Functional Outcomes Sleep Questionnaire (FOSQ)
1-year
18.30 score on a scale
Standard Deviation 1.82
18.63 score on a scale
Standard Deviation 1.95

SECONDARY outcome

Timeframe: Change from baseline at 6 months and 1 year

Population: 14 participants were lost to follow up prior to 6 months testing.

This informant-rated composes of multiple subscales, to evaluate cognitively based functional abilities in older adults. The factor structure of Everyday Cognition was assessed with confirmatory factor analysis, which supported a 7-factor model including 1 global factor and 6 domain-specific factors (Everyday Memory, Language, Visuospatial Abilities, Planning, Organization, and Divided Attention). The total mean score ranges from 0 to 57. A higher score indicates a worse outcome.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=29 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
n=25 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Everyday Function Outcome: Everyday Cognition (E-Cog)
Baseline
1.46 score on a scale
Standard Deviation 0.54
1.29 score on a scale
Standard Deviation 0.41
Everyday Function Outcome: Everyday Cognition (E-Cog)
6 months
1.35 score on a scale
Standard Deviation 0.36
1.43 score on a scale
Standard Deviation 0.52
Everyday Function Outcome: Everyday Cognition (E-Cog)
1-year
1.35 score on a scale
Standard Deviation 0.51
1.52 score on a scale
Standard Deviation 0.70

SECONDARY outcome

Timeframe: Change from baseline at 1 year

Population: Participants who completed the study and improved on ADCS-CGIC scores at 1year adjusted for age, race and marital status.

Global change (progression) will be assessed using ADCS-CGIC at 1 year. It has 8 categories as markedly improved, moderately improved, minimally improved, not changed, minimally worse, moderately worse, markedly worse, missing response.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=41 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)
ADCS-CGIC Improved
34 participants
Alzheimer's Disease Cooperative Study - Clinicians' Global Impression of Change Scale (ADCS-CGIC)
ADCS-CGIC Unimproved
7 participants

SECONDARY outcome

Timeframe: Change from baseline at 1 year

Population: Study participants who completed the study and improved on CDR data adjusted for age, race and marital status.

Cognitive ability will be assessed and staged using CDR. It contains 6 items (memory, orientation, judgement and problem solving, community affairs, home and hobbies, personal care), and each item ranges from 0 to 3. The total score ranges from 0 to 18, a higher score indicates a worse outcome. We observed the change of CDR score from baseline to 1-year follow up. Improved on CDR was defined as a lower CDR score compared to baseline. Reference group is unimproved, defined as worsened (higher) CDR or unchanged CDR compared to baseline.

Outcome measures

Outcome measures
Measure
MCI/OSA/CPAP Adherent
n=42 Participants
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
MCI/OSA/CPAP Non-adherent
Device: Continuous Positive Airway Pressure \[CPAP\]. Included those diagnosed with mild cognitive impairment (MCI) and obstructive sleep apnea (OSA). The diagnostic criteria for OSA was defined as an Apnea Hypopnea Index (AHI) score of greater than or equal to 10. CPAP prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year. Continuous Positive Airway Pressure \[CPAP\]: Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
Clinical Dementia Rating Scale (CDR)
CDR Improved
21 participants
Clinical Dementia Rating Scale (CDR)
CDR Unimproved
21 participants

Adverse Events

MCI/OSA/CPAP Adherent

Serious events: 5 serious events
Other events: 0 other events
Deaths: 0 deaths

MCI/OSA/CPAP Non-adherent

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
MCI/OSA/CPAP Adherent
n=29 participants at risk
Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use equal to or greater than 4 hours per night over one year.
MCI/OSA/CPAP Non-adherent
n=25 participants at risk
Device: CPAP. Included those diagnosed with MCI and OSA. The diagnostic criteria for OSA was defined as an AHI score of greater than or equal to 10. CPAP was prescribed for nightly use. Mean CPAP use less than 4 hours per night over one year.
Cardiac disorders
Heart irregularities
6.9%
2/29 • Number of events 2 • 1 year
0.00%
0/25 • 1 year
General disorders
Hospital admission
3.4%
1/29 • Number of events 1 • 1 year
0.00%
0/25 • 1 year
Injury, poisoning and procedural complications
Bleeding
3.4%
1/29 • Number of events 1 • 1 year
0.00%
0/25 • 1 year
Musculoskeletal and connective tissue disorders
Surgery
3.4%
1/29 • Number of events 1 • 1 year
0.00%
0/25 • 1 year

Other adverse events

Adverse event data not reported

Additional Information

Dr. Kathy C. Richards

George Mason University

Phone: (703) 946-3725

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place